A randomized, placebo-controlled, double blind Phase 1 trial of the Aβ vaccine, AV-1959R, in non-clinically impaired participants: prelude for secondary preventive therapy in preclinical AD

Molecular Neurodegeneration · Published 2026-07-22 · DOI 10.1186/s13024-026-00980-y

Free full text

Authors (20)

Armine Hovakimyan, Hovhannes Madoyan, Zahra Najarzadeh, Garri Chilingaryan, Irina Petrushina, Grigor Mamikonyan, Ekaterina Lebedeva, Aleksandr Zaitsev, Kimiya Mansour, Thomas P. O’Malley, Shane Gonen, Roman Kniazev, Nikolai Petrovsky, Alexander Grinberg, Robert C. Alexander, Lon S. Schneider, Ravshan Ataullakhanov, Charles Glabe, Anahit Ghochikyan, Michael G. Agadjanyan

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Hovakimyan, A., Madoyan, H., Najarzadeh, Z., et al. (2026). A randomized, placebo-controlled, double blind Phase 1 trial of the Aβ vaccine, AV-1959R, in non-clinically impaired participants: prelude for secondary preventive therapy in preclinical AD. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-026-00980-y

Related articles